HOME >> BIOLOGY >> NEWS
Extra-aggressive form of idiopathic pulmonary fibrosis identified

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disorder from which most patients die within 5 years after diagnosis. The disease is characterized by the insidious onset of dyspnea or cough and usually evolves slowly.

Now, Selman and coworkers present in an article published in the online, open-access journal PLoS ONE on Wednesday 30th May, strong evidence indicating that a subset of IPF patients has a short duration of symptoms before diagnosis and display an accelerated clinical course to end-stage disease. The authors postulate that these "rapid progressor" patients, predominantly smoking males, represent a distinct clinical phenotype compared with the usual "slow progressors" patients.

"These findings highlight the variability in the progression and outcome of IPF, and may explain, in part, the difficulty in obtaining significant and reproducible results in studies of therapeutic interventions in patients with IPF," said Dr Selman, who is the Director of Research at the National Institute of Respiratory Research in Mexico City and the lead author on this publication. "They also suggest that physicians should pay more attention to the time of onset of symptoms, and to look for other signs that allow the identification of these rapid progressor patients".

In this study the authors performed global gene expression analysis and other molecular studies in a subset of patients and identified a number of genes that were differentially expressed in both groups, suggesting that rapid progressors are biologically distinct from slow progressors.

"While preliminary, these results may allow investigators to identify biomarkers of disease progression," said Dr King, who is the Chief of Medicine at San Francisco General Hospital and an internationally renowned expert in research and management of pulmonary fibrosis.

The senior author on this paper, Dr Naftali Kaminski, who is the Director
'"/>

Contact: Moiss Selman
mselmanl@yahoo.com.mx
Public Library of Science
29-May-2007


Page: 1 2

Related biology news :

1. Gene expression patterns predict rapid decline in idiopathic pulmonary fibrosis patients
2. A candidate gene for familial idiopathic pulmonary fibrosis identified
3. New approach to pulmonary hypertension shows promise
4. Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness
5. NIH gives PITT $13 million grant for chronic obstructive pulmonary disease research
6. Scientific meeting on pulmonary hypertension, December 7-8
7. Leveling the field for babies with persistent pulmonary hypertension
8. U-M scientists target key cells and signals that trigger pulmonary fibrosis
9. First different black/white mechanism in pulmonary fibrosis/scleroderma identified
10. Against pulmonary fibrosis
11. First report of cancer drug Gleevec as new target therapy for pulmonary hypertension

Post Your Comments:
(Date:7/2/2015)... June 25, 2015 ... addition of the "Natural Language Processing Market ... IVR, OCR, Pattern & Image Recognition) - Worldwide ... The key vendors occupying the market ... Corporation, Microsoft Corporation, NetBase Solutions, SAS Institute Inc., ...
(Date:7/2/2015)... , June 25, 2015 ... of the "Next Generation Biometrics Market by Application, ... report to their offering. The next ... by 2020, at a CAGR of 17.9% between 2015 ... leading application for the market. Safran SA ...
(Date:7/2/2015)... , July 2, 2015 Fingerprint Cards ... FPC1035, FPC1145 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... sensors will be used by smartphone manufacturers in ... included in the communicated revenue guidance of approximately 2,200 MSEK ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
(Date:7/6/2015)... -- Research and Markets ( ... "Biotechnology for the Non-Biotechnologist" conference to ... ideal for non-Scientists and Scientists needing to understand ... biotechnology. Ideal for Non-Scientists and Scientists ... and potential of biotechnology Why you ...
(Date:7/6/2015)... 6, 2015  Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), a company ... , Viveve,s Chief Executive Officer, and Scott Durbin , ... July 9, 2015. , , , DATE:    ... , , TIME:     , , , 12:15 PM ... , http://tinyurl.com/viveve   ,    ...
(Date:7/6/2015)... PRINCETON, N.J. , July 6, 2015 Navitas, a leading ... Latin America hub in Bogota, Colombia ... advantage of the many benefits provided by Colombia , ... Logo - http://photos.prnewswire.com/prnh/20150703/228239LOGO ... location, allows US based clients to communicate with Navitas regulatory ...
(Date:7/6/2015)... ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) ... Novella Clinical (Novella), to conduct the phase 3 ... glioblastoma. Novella is a full-service, global clinical research organization ... oncology companies. The ICT-107 phase 3 trial will include ... Europe and Canada , ...
Breaking Biology Technology:Viveve to Webcast Live at VirtualInvestorConferences.com 2Viveve to Webcast Live at VirtualInvestorConferences.com 3Navitas Launches Latin American Regulatory Operations Hub in Bogota, Colombia 2Navitas Launches Latin American Regulatory Operations Hub in Bogota, Colombia 3ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2
Cached News: